Brian Allen, MD
Cardiovascular Disease · Brighton, CONPI 1831516848
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,791 of the $11,178 with a category attached, or 87.6%. 30 manufacturers reported payments, led by Philips North America LLC at 28.1% of the total. Reporting peaked in 2024 at $6,770 and has fallen 79.8% since, to $1,368 in 2025.
Across 223 payments — averaging $50.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Philips North America LLC$3K
- Penumbra, Inc.$2K
- Inari Medical, Inc.$2K
- Shockwave Medical, Inc$1K
- Abbott$570
- Medtronic$429
- plus $2K from 24 others
What the payments were for
- Travel & lodging$1,23811%
- Food & beverage$9,79188%
- Education$1491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Philips North America LLC | 40 | $3,138 |
| Penumbra, Inc. | 21 | $1,747 |
| Inari Medical, Inc. | 18 | $1,645 |
| Shockwave Medical, Inc | 10 | $1,239 |
| Abbott | 17 | $570 |
| Medtronic | 4 | $429 |
| Novartis | 29 | $355 |
| Bolton Medical Inc | 5 | $290 |
| E.r. Squibb & Sons, L.L.C. | 11 | $224 |
| Novo Nordisk | 17 | $166 |
| Johnson & Johnson | 5 | $153 |
| Cardiovascular Systems Inc. | 1 | $140 |
| Biotronik Inc. | 3 | $127 |
| Pfizer | 6 | $116 |
| Amgen | 6 | $113 |
| Merck | 5 | $99 |
| Cardiva Medical, Inc. | 3 | $99 |
| AstraZeneca | 4 | $97 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $89 |
| Irhythm Technologies, Inc. | 2 | $52 |
| Inspire Medical Systems, Inc. | 2 | $49 |
| Baxter Healthcare | 1 | $45 |
| Atricure, Inc. | 1 | $35 |
| Boston Scientific | 1 | $33 |
| Scpharmaceuticals Inc. | 2 | $29 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $29 |
| Impulse Dynamics (USA) Inc. | 1 | $23 |
| Siemens Medical Solutions USA, Inc. | 1 | $19 |
| Cordis US CORP. | 1 | $16 |
| Abiomed | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$1,292
- CT THROMBECTOMY SYSTEM KIT$1,292
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,103
- (9520) IGT Devices Undivided$955
- Indigo System$869
- (BR0) Coronary Atherectomy$488
- (BS0) Mechanical Atherectomy$295
- (BR5) Peripheral IVUS$204
- RESOLUTE ONYX$149
- RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM$143
- Diamondback Peripheral$140
- Diamondback Coronary$140
- Assurity Pacemaker$129
- PHOENIX$123
- HawkOne$113
- COBALT DR MRI SURESCAN$112
How this compares
$11,178 in reported general payments places this provider in the 85th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 109 | $76,979 |
| EliquisApixaban | 98 | $63,176 |
| OzempicSemaglutide | 43 | $45,169 |
| XareltoRivaroxaban | 24 | $22,585 |
| BrilintaTicagrelor | 35 | $15,158 |
| EntrestoSacubitril/Valsartan | 16 | $14,615 |
| JardianceEmpagliflozin | 16 | $12,787 |
| Repatha SureclickEvolocumab | 14 | $9,759 |
| Ranolazine ErRanolazine | 29 | $1,907 |
| Valsartan | 27 | $1,203 |
| ClopidogrelClopidogrel Bisulfate | 98 | $1,049 |
| Rosuvastatin Calcium | 82 | $973 |
| Metoprolol Succinate | 57 | $738 |
| Torsemide | 25 | $643 |
| Nebivolol Hcl | 18 | $607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $97 | $92,137144 claims |
| PfizerEliquis | $116 | $63,17698 claims |
| Novo NordiskOzempic | $166 | $45,16943 claims |
| Johnson & JohnsonXarelto | $153 | $22,58524 claims |
| NovartisEntresto | $355 | $14,61516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Brighton
- Donald RaborBrighton$8K
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
- Andrew FreemanDenver$454K
- William SauerAurora$365K
- Jeffrey BooneGreenwood Village$287K
- Rhonda MiyasakaAurora$128K
- Gregory SchwartzAurora$122K
- Deborah JalowiecColorado Springs$106K
- Edward GillAurora$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.